<DOC>
	<DOCNO>NCT01506609</DOCNO>
	<brief_summary>The Study Evaluating Efficacy And Tolerability Veliparib Combination Temozolomide Veliparib/Placebo Combination Carboplatin Paclitaxel Subjects locally recurrent Breast Cancer amenable therapy curative intent , metastatic breast cancer document ( BRCA1 ) ( BRCA2 ) deleterious germline mutation .</brief_summary>
	<brief_title>The Study Evaluating Efficacy And Tolerability Of Veliparib Combination With Temozolomide In Combination With Carboplatin Paclitaxel Versus Placebo Subjects With BRCA1 BRCA2 Mutation Metastatic Breast Cancer</brief_title>
	<detailed_description>Subjects randomize 1:1:1 ratio one three treatment group . The safety treatment group assess evaluate study drug exposure , adverse event , serious adverse event , death , change laboratory determination , vital sign parameter . The Clinical Benefit Rate ( CBR ) Objective Response Rate ( ORR ) well Progression-free survival ( PFS ) use Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 assess . Study visit conduct accord protocol schedule randomization group . Study visit include physical examination , laboratory blood sample collection , assessment vital sign , medical history urinalysis . 12-lead Electrocardiogram ( ECG ) perform protocol specify visit .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer either locally recurrent metastatic . Locally recurrent disease must amenable surgical resection radiation curative intent . Must document deleterious Breast Cancer Gene BRCA1 BRCA2 germline mutation . If Human Epidermal Growth Factor Receptor ( HER2 ) positive , subject must receive progress least one prior standard HER2 direct therapy subject must ineligible receive antiHER2 therapy . Measurable nonmeasurable ( radiologically evaluable ) disease RECIST ( Response Evaluation Criteria Solid Tumors ) criteria 1.1 . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 . Subject must adequate bone marrow , renal hepatic function . Subject must pregnant plan conceive child . Received anticancer agent ( ) investigational agent within 21 day prior C1D1 , radiotherapy within 28 day prior Cycle 1 Day 1 More 2 prior line cytotoxic chemotherapy Prior treatment breast cancer temozolomide , platinum agent , Poly ( ADP ribose ) Polymerase ( PARP ) inhibitor . Prior taxane therapy metastatic breast cancer . A history evidence brain metastasis leptomeningeal disease . A history uncontrolled seizure disorder Preexisting neuropathy cause excess Grade 1 Known history allergic reaction cremophor/paclitaxel Clinical significant uncontrolled condition â€ '' active infection , myocardial infarction , stroke , transient ischemic attack , psychiatric illness/social situation would limit compliance . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>BRCA1 mutation carrier</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>TMZ</keyword>
	<keyword>Recurrent breast cancer</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>ABT-888</keyword>
	<keyword>veliparib</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Locally recurrent</keyword>
	<keyword>Temodal</keyword>
	<keyword>BRCA2 mutation carrier</keyword>
	<keyword>PARP</keyword>
</DOC>